The six long-term winners I'd buy for a post-Covid-19 world
Professional investor William Meadon of the JPMorgan Claverhouse Investment Trust picks six solid stocks that have held up well through lockdown and will benefit from a wider economic recovery.
We see light at the end of the tunnel following the Covid-19 pandemic. While there are still significant hurdles to face before “normal” life can resume, we are optimistic that the long-term outlook for the UK is one of sustained growth.In the short term, growth may be uneven as markets across the globe begin to find their feet. British stocks are well placed to benefit from this wider recovery, although residual Brexit headwinds remain.
We believe that many of the key drivers and themes that have accelerated over the past year, such as online retail and home improvement, will remain in place. We therefore remain focused on the long term, seeking out companies with strong balance sheets, consistent cash generation and resilient business models.
Housebuilders have solid foundations
We have been long-term advocates of housebuilders, with companies such as Persimmon (LSE: PSN), Barratt Developments (LSE: BDEV) and Bellway(LSE: BWY) all forming part of our portfolio. While many companies were forced to suspend dividend payouts this year, housebuilders, who were able to restart operations in April and May, got back on track quickly. Persimmon, for example, was one of the first housebuilders back in production and managed to provide a special dividend to investors over the summer.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Many housebuilders entered this crisis with strong balance sheets. This is largely down to good management teams that have weathered previous market downturns and, as a result, emerged stronger. Many of these companies remain compelling, trading on single-digit multiples based on their earnings forecasts for next year, and should be able to maintain their dividends in the next year.
First among financials
When it comes to the financial sector, life assurers often stand out for their higher-quality loans and reduced exposure to interest-rate volatility. Banks tend to have greater exposure to consumer and small business-lending, which is often the first portion of the credit market to see rising default levels during recessionary periods.
Since the onset of the pandemic, many of Britain’s largest banks have cancelled their dividends due to regulatory pressures. On the other hand, Legal & General (LSE: LGEN), Phoenix Group (LSE: PHNX) and Prudential (LSE: PRU) have kept paying dividends – a welcome development in a world where yield is scarce.
A retailer with roaring online sales
The retail sector faces a number of challenges, but we see opportunities among operators with a strong online presence and those catering to the growing theme of home improvement. Bricks-and-mortar retailer Dunelm (LSE: DNLM) was already taking market share before lockdown.
Others in the sector are struggling to keep up in terms of product offering, technology and marketing spend. To survive and thrive as a retailer, data and technology are key. The company’s newly upgraded website has benefited from significant investment, and online sales are up by 100% year-on-year. Dunelm’s sharp focus on value for money also resonates with its customers and, as the economic backdrop remains uncertain, it should further benefit the company.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
William Meadon is manager of the JPMorgan Claverhouse investment trust.
-
Ben Cohen: The Ben & Jerry’s co-founder who wants to break away from Unilever
Ben Cohen of Ben & Jerry’s ice cream is seeking to break away from Unilever, the conglomerate he sold out to in 2000. It’s a battle for the soul of the brand synonymous with corporate do-gooding.
By Jane Lewis
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves